Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
about
Anti-vascular endothelial growth factor for proliferative diabetic retinopathyAnti-vascular endothelial growth factor for diabetic macular oedemaAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAnti-vascular endothelial growth factor for proliferative diabetic retinopathyAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaRanibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessThe Vitreomacular Interface in Diabetic RetinopathyA review of anti-VEGF agents for proliferative diabetic retinopathyInhibition of oxygen-induced ischemic retinal neovascularization with adenoviral 15-lipoxygenase-1 gene transfer via up-regulation of PPAR-γ and down-regulation of VEGFR-2 expressionTreatment of diabetic retinopathy: Recent advances and unresolved challengesMulti-modal proteomic analysis of retinal protein expression alterations in a rat model of diabetic retinopathyAge-related alterations in retinal neurovascular and inflammatory transcriptsAttenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complicationVascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathyUse of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Evolving European guidance on the medical management of neovascular age related macular degeneration.Pharmacotherapies for diabetic retinopathy: present and future.Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.A proposed new classification for diabetic retinopathy: the concept of primary and secondary vitreopathy.Diabetic retinopathy: an updateEndoplasmic reticulum stress and diabetic retinopathy.Surgical management of retinopathy of prematurity.Emerging drugs for diabetic retinopathy.Intravitreal bevacizumab for treatment of diabetic macular edemaIntravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathyIncreased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferationPegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular EdemaNew Therapeutic Approaches in Diabetic Retinopathy.Use of antivascular endothelial growth factor for diabetic macular edema.Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.Treatment of proliferative diabetic retinopathy with anti-VEGF agents.Neovascular glaucomaIntravitreal bevacizumab in retinopathy of prematurity: an interventional case series.Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF EraEffect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbitsPanretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
P2860
Q24187858-D1A95EEC-2ECA-4232-8D07-9FE563420632Q24193083-3627B4F8-60E0-4A24-8080-3FC4544A85BCQ24202071-1353CF27-F9FF-4160-9862-4D6605F0A7A4Q24236189-E838EA63-9DA4-4D98-878E-447DF8F27A21Q24240165-997BA1DD-32DA-46C3-9B63-226A06CF5FEFQ24242242-A0C4307B-C6CC-42A1-96A3-AFBD24C12C3EQ24674358-4A26E3EE-5653-480F-9405-12C556172A9EQ26783404-41250A46-C8A7-4056-B9E7-F05373461BF2Q27025643-DDF928FF-E134-47A3-B45C-DAE26142F1D4Q27332433-8346DC11-E8BD-48CD-9F7B-F051AF0EEE5DQ28067491-9FE74D91-0B79-4C19-8343-E8333C7E6BCEQ28476732-8ACA3BF5-02CE-4739-92D6-3CA2F56CDC3FQ28570411-60FB7F47-D0E3-4085-8AC4-77D518F5E3E7Q28829757-D4537783-3F7D-4C6B-A82C-C626E9C43CA7Q30244247-C32CF87A-9817-4325-A363-7D6840E11C03Q30845192-0351034B-A00F-4A0C-8F63-C0288021A2CEQ30979491-F34075A5-E688-4635-96F9-A488CF70ECB4Q31061150-9E4F0092-2582-45F3-9AF4-6A9B21246A5CQ33255038-71D84CCC-4742-4288-B1B7-3C7155B648EEQ33294882-29A65028-0A28-4D2B-9CD7-901733BDD151Q33303367-208CF194-8553-490D-927E-7B5AEF832E3BQ33312306-7930352B-DFCD-432F-B238-E1FB69CD3BCFQ33328784-3317F943-9CF5-4FDE-858F-08E0FEA4DE2AQ33352111-BE7F5E33-7880-433A-B4B9-A6ACDA54AD6FQ33366951-0A883643-7E38-4AA6-BA8F-857DCEADC63BQ33388498-B8EA2B48-96B2-4AD5-A0D5-811B664B514AQ33425236-F59751C7-F958-4781-9815-3622D6829226Q33492339-264917FC-F401-4726-9B47-EA5C55B4F184Q33518352-3A960DB6-A8E2-4003-8D4E-D526759C36E8Q33546338-3CD5FF81-2F0F-4466-A9C1-FD1B3B51001BQ33583037-6B3C258A-35C2-4EF9-AEA9-863EB771BFE5Q33599732-A75E3746-4A35-4B43-89AA-0C9DEB8CCD1EQ33805314-B9259547-D256-42A3-9838-26DFBB397C34Q33812021-79D9441B-D104-44DD-AA45-641C483A16F6Q33855412-DD1F7E76-F24C-40EA-AC26-23028823AA30Q33873875-0ED7BC5A-C23E-44BC-BFDD-111021B68DC1Q33902419-B3DCA5CC-60D0-4583-B0ED-D919BCC50F29Q33905676-B38351A2-8D00-4429-BB6B-6CE9DF0842FAQ33911625-6F1B6F38-514F-4578-A70A-F50C8E8CD190Q33949871-291B4776-F300-422F-9C4C-9C9CEDC7D157
P2860
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@ast
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@en
type
label
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@ast
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@en
prefLabel
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@ast
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@en
P1433
P1476
Intravitreal bevacizumab (Avas ...... icated by vitreous hemorrhage.
@en
P2093
Yale L Fisher
P304
P356
10.1097/00006982-200603000-00004
P577
2006-03-01T00:00:00Z